Home Business Alexion Pharmaceuticals, Inc. (ALXN) Rating Reiterated by Robert W. Baird

Alexion Pharmaceuticals, Inc. (ALXN) Rating Reiterated by Robert W. Baird

150
0
SHARE

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s stock had its “neutral” rating reissued by investment analysts at Robert W. Baird in a note issued to investors on Saturday. They currently have a $145.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s price target would suggest a potential upside of 0.97% from the company’s previous close.
Other equities research analysts have also recently issued reports about the stock. Brean Capital started coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday, October 4th. They set a “buy” rating and a $221.00 price target on the stock. Cowen and Company reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, September 22nd. Citigroup Inc. boosted their price target on shares of Alexion Pharmaceuticals from $154.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, September 20th. Goldman Sachs Group, Inc. (The) raised shares of Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $158.00 price target on the stock in a research report on Friday, October 28th. Finally, Deutsche Bank AG started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, November 3rd. They set a “buy” rating and a $164.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $172.85.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 143.61 on Friday. The company has a market cap of $32.19 billion, a PE ratio of 87.57 and a beta of 1.40. Alexion Pharmaceuticals has a 52 week low of $109.12 and a 52 week high of $169.84. The firm’s 50-day moving average is $122.56 and its 200-day moving average is $125.32.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The firm had revenue of $799 million for the quarter, compared to analysts’ expectations of $787.07 million. During the same period in the previous year, the firm posted $1.16 EPS. The company’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, analysts expect that Alexion Pharmaceuticals will post $4.64 EPS for the current fiscal year.
In related news, Director Leonard Bell sold 1,300 shares of the stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $135.28, for a total transaction of $175,864.00. Following the sale, the director now owns 406,589 shares in the company, valued at approximately $55,003,359.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Carsten Thiel sold 4,584 shares of the stock in a transaction that occurred on Friday, October 14th. The stock was sold at an average price of $120.28, for a total transaction of $551,363.52. Following the sale, the executive vice president now owns 32,741 shares in the company, valued at approximately $3,938,087.48. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Wetherby Asset Management Inc. raised its stake in Alexion Pharmaceuticals by 2.1% in the second quarter. Wetherby Asset Management Inc. now owns 10,068 shares of the biopharmaceutical company’s stock valued at $1,176,000 after buying an additional 208 shares in the last quarter. Bank of Montreal Can purchased a new stake in Alexion Pharmaceuticals during the second quarter valued at about $34,314,000. Los Angeles Capital Management & Equity Research Inc. raised its stake in Alexion Pharmaceuticals by 6,392.9% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 118,690 shares of the biopharmaceutical company’s stock valued at $14,544,000 after buying an additional 116,862 shares in the last quarter. American International Group Inc. raised its stake in Alexion Pharmaceuticals by 0.8% in the third quarter. American International Group Inc. now owns 103,671 shares of the biopharmaceutical company’s stock valued at $12,704,000 after buying an additional 795 shares in the last quarter. Finally, Strs Ohio raised its stake in Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock valued at $65,398,000 after buying an additional 52,710 shares in the last quarter. Institutional investors and hedge funds own 94.74% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

What are top analysts saying about Alexion Pharmaceuticals Inc.?

LEAVE A REPLY

Please enter your comment!
Please enter your name here